Le Lézard
Classified in: Health, Science and technology
Subject: PDT

careviso: Now Launching Patient Health Plan Discovery


FALLS CHURCH, Va., Nov. 30, 2023 /PRNewswire/ -- careviso, a leading healthcare technology company, is launching a new offering within their existing prior authorization business: patient health plan coverage detection, or "Discovery."

careviso launches Patient Health Plan Discovery for prior authorization and transparency services

Annually, careviso processes more than one million prior authorizations, making a significant impact on streamlining the healthcare process. Recognizing a critical pain point for healthcare providers in confirming patient coverage, Discovery is poised to empower careviso's expanding customer base by capturing previously unknown health plan insurance information.

Transparency Redefined
In a landscape where 92.1% of people had health insurance at some point in 2022, identifying accurate health insurance information remains a challenge. Many health care claims revert to self-pay due to difficulties in determining the correct insurance details, initiating lengthy collection cycles with inefficient labor hours and administrative burdens. Discovery addresses this issue head-on, aiming to significantly reduce bad debt write-offs and streamline the collection process.

Enhancing Healthcare Transparency Through Technology
As an integral component of careviso's advanced technology solutions, Discovery plays a pivotal role in achieving the company's mission of bringing true transparency to healthcare. By providing a comprehensive view, careviso empowers physicians and all healthcare providers to make informed decisions. This, in turn, leads to increased access to care, substantial cost savings, and improved revenue management for healthcare organizations.

Streamlined Support for Providers: Accelerating the Prior Authorization Process
careviso's cutting-edge technology simplifies and accelerates the prior authorization process, effectively reducing administrative burdens and costs for healthcare providers. This efficiency translates into increased and faster access to necessary treatments for patients, ensuring that they receive timely care when they need it most.

As careviso continues to grow and innovate, they remain dedicated to their mission of fostering transparency, enhancing efficiency, and improving patient care within the healthcare industry. Through cutting-edge technology and unwavering commitment, careviso is a driving force behind a brighter future for healthcare. To learn more, visit: www.careviso.com and click on the "contact" button.

For media inquiries or more information about careviso, please email:

[email protected]

7600 Leesburg Pike, Suite 220 East
Falls Church, VA 22043
www.careviso.com

SOURCE Careviso


These press releases may also interest you

at 02:44
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its enterprise imaging solution to yet another healthcare provider in the US Midwest. The healthcare provider will utilize the radiology module to unify the...

at 02:05
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the...

at 02:00
RLDatix, the leading global provider of connected healthcare operations software and services, has finalized the acquisition of Breitenbach Software Engineering GmbH ("Breitenbach"), a Germany-based integrated solutions provider specializing in...

at 01:35
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its preliminary results for the year ended 31 December 2023 on Thursday, 14 March 2024....

at 01:00
MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indicationsDedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for...



News published on and distributed by: